IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.089 AUD | +1.14% |
|
+12.66% | -38.62% |
| Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
| Apr. 30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 10.85M 7.22M | Sales 2025 * | 19.15M 12.75M | Capitalization | 178M 119M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -13.98M | Net income 2025 * | -14M -9.32M | EV / Sales 2024 * | 14.2 x |
| Net cash position 2024 * | 24.42M 16.25M | Net cash position 2025 * | 13.15M 8.75M | EV / Sales 2025 * | 8.61 x |
| P/E ratio 2024 * |
-8.9
x | P/E ratio 2025 * |
-13.8
x | Employees | 76 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on ImpediMed Limited
| 1 day | +1.14% | ||
| 1 week | +12.66% | ||
| Current month | +5.95% | ||
| 1 month | -5.32% | ||
| 3 months | +5.95% | ||
| 6 months | -34.07% | ||
| Current year | -38.62% |
1 week
0.08
0.09
1 month
0.080.11
Current year
0.080.16
1 year
0.080.24
3 years
0.050.24
5 years
0.030.24
10 years
0.031.82
| Managers | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | Jan. 07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 23-09-27 |
Steven Chen
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | Jan. 07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 23-09-27 |
| Chairman | - | 23-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.089 | +1.14% | 1 323 917 |
| 24-05-16 | 0.088 | +4.76% | 2,009,265 |
| 24-05-15 | 0.084 | +5.00% | 3,159,941 |
| 24-05-14 | 0.08 | +1.27% | 834,952 |
| 24-05-13 | 0.079 | 0.00% | 2,062,053 |
Delayed Quote Australian S.E., May 17, 2024 at 02:10 am EDT
More quotes
ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Companyâs SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.088
AUD
Average target price
0.1753
AUD
Spread / Average Target
+99.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.62% | 119M | |
| +12.50% | 228B | |
| +14.52% | 196B | |
| +17.51% | 141B | |
| +28.96% | 110B | |
| +1.37% | 65.88B | |
| +18.16% | 54.3B | |
| +7.63% | 52.39B | |
| +10.95% | 45.22B | |
| +5.10% | 37.12B |
- Stock Market
- Equities
- IPD Stock
